EGFR and non-small cell lung carcinoma: We next tested the impacts on EGFR inhibition and subsequent downstream signals with combinations of mavelertinib or naquotinib with JBJ-125 in the NSCLC cell line H3255GR, which harbors EGFR(L858R/T790M).